NASDAQ:RNA Avidity Biosciences (RNA) Stock Price, News & Analysis → This Apple-like Innovator is Revolutionizing Healthcare (From Wall Street Star) (Ad) Free RNA Stock Alerts $27.81 -1.81 (-6.11%) (As of 02:34 PM ET) Add Compare Share Share Today's Range$27.65▼$30.0050-Day Range$22.73▼$29.6252-Week Range$4.82▼$30.84Volume829,068 shsAverage Volume1.13 million shsMarket Capitalization$2.66 billionP/E RatioN/ADividend YieldN/APrice Target$41.33 Stock AnalysisStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipShort InterestSocial MediaStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipShort InterestSocial Media Get Avidity Biosciences alerts: Email Address Avidity Biosciences MarketRank™ Stock AnalysisAnalyst RatingBuy3.00 Rating ScoreUpside/Downside46.1% Upside$41.33 Price TargetShort InterestBearish11.91% of Shares Sold ShortDividend StrengthN/ASustainabilityN/ANews Sentiment0.47Based on 16 Articles This WeekInsider TradingSelling Shares$7.66 M Sold Last QuarterProj. Earnings GrowthDecreasingFrom ($3.10) to ($3.28) Per ShareSee Full Details Hide Full Details Overall MarketRank™New Rank-Based ScoringMarketRank™ is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.0.93 out of 5 starsMedical Sector809th out of 921 stocksPharmaceutical Preparations Industry376th out of 425 stocks 3.5 Analyst's Opinion Consensus RatingAvidity Biosciences has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 6 buy ratings, no hold ratings, and no sell ratings.Amount of Analyst CoverageAvidity Biosciences has only been the subject of 4 research reports in the past 90 days.Read more about Avidity Biosciences' stock forecast and price target. Previous Next 0.0 Short Interest Percentage of Shares Shorted11.91% of the outstanding shares of Avidity Biosciences have been sold short.Short Interest Ratio / Days to CoverAvidity Biosciences has a short interest ratio ("days to cover") of 10, which indicates bearish sentiment.Change versus previous monthShort interest in Avidity Biosciences has recently increased by 6.85%, indicating that investor sentiment is decreasing significantly. Previous Next 0.0 Dividend Strength Dividend YieldAvidity Biosciences does not currently pay a dividend.Dividend GrowthAvidity Biosciences does not have a long track record of dividend growth. Previous Next N/A Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreThere is no current Upright™ data available for RNA. Previous Next 3.0 News and Social Media Coverage News SentimentAvidity Biosciences has a news sentiment score of 0.47. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This news sentiment score is similar to the average news sentiment of Medical companies.News Coverage This WeekMarketBeat has tracked 16 news articles for Avidity Biosciences this week, compared to 3 articles on an average week.Search Interest21 people have searched for RNA on MarketBeat in the last 30 days. This is an increase of 110% compared to the previous 30 days.MarketBeat Follows5 people have added Avidity Biosciences to their MarketBeat watchlist in the last 30 days. This is an increase of 67% compared to the previous 30 days. Previous Next 0.8 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Avidity Biosciences insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $7,662,051.00 in company stock.Percentage Held by InsidersOnly 3.68% of the stock of Avidity Biosciences is held by insiders.Read more about Avidity Biosciences' insider trading history. Previous Next 0.0 Earnings and Valuation Earnings GrowthEarnings for Avidity Biosciences are expected to decrease in the coming year, from ($3.10) to ($3.28) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Avidity Biosciences is -9.59, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Avidity Biosciences is -9.59, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioAvidity Biosciences has a P/B Ratio of 3.26. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.Read more about Avidity Biosciences' valuation and earnings. Previous Next See Top Rated MarketRank™ Stocks Here Ad InvestorPlaceMust-See: Elon’s New Invention is Absolutely InsaneSee what Elon Musk's new invention does and how it works… You will NOT believe it.Click here to see it About Avidity Biosciences Stock (NASDAQ:RNA)Avidity Biosciences, Inc., a biopharmaceutical company, engages in the delivery of RNA therapeutics. It develops antibody oligonucleotide conjugates (AOC) that are designed to treat diseases previously untreatable with RNA therapeutics. The company's lead product candidate AOC 1001 for the treatment of myotonic dystrophy type 1, a rare monogenic muscle disease that is in phase 1/2 clinical trial. Its other products in pipeline include AOC 1044 for the treatment of duchenne muscular dystrophy, which is under phase 1/2 clinical development trial; and AOC 1020 to treat facioscapulohumeral muscular dystrophy that is in phase 1/2 clinical trial. The company is developing products for rare skeletal muscle and rare cardiac diseases. Avidity Biosciences, Inc. was incorporated in 2012 and is headquartered in San Diego, California.Read More RNA Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart RNA Stock News HeadlinesMay 22 at 6:14 AM | insidertrades.comArthur A. Levin Sells 5,000 Shares of Avidity Biosciences, Inc. (NASDAQ:RNA) StockMay 17, 2024 | insidertrades.comAvidity Biosciences, Inc. (NASDAQ:RNA) CFO Sells $2,121,000.00 in StockMay 8, 2024 | insidertrades.comSarah Boyce Sells 28,000 Shares of Avidity Biosciences, Inc. (NASDAQ:RNA) StockMay 23 at 6:00 AM | investorplace.comDip Then Rip? 3 Nasdaq Stocks to Buy Before the ReboundMay 22 at 4:10 AM | americanbankingnews.comAvidity Biosciences, Inc. (NASDAQ:RNA) Receives Consensus Rating of "Buy" from AnalystsMay 21 at 6:37 PM | markets.businessinsider.comAvidity Biosciences Poised for Growth: Buy Rating Affirmed Amidst Encouraging Competitive LandscapeMay 21 at 4:05 PM | prnewswire.comAvidity Biosciences Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)May 19, 2024 | investing.comAvidity Biosciences Inc (RNA)May 19, 2024 | seekingalpha.comAvidity Biosciences: Strong Buy With Promising RNA Therapeutics PipelineMay 19, 2024 | finance.yahoo.comBank of America Predicts up to ~200% Surge for These 2 ‘Strong Buy’ StocksMay 18, 2024 | americanbankingnews.comMichael F. Maclean Sells 75,000 Shares of Avidity Biosciences, Inc. (NASDAQ:RNA) StockMay 15, 2024 | prnewswire.comAvidity Biosciences Announces Appointment of Simona Skerjanec to Board of DirectorsMay 14, 2024 | americanbankingnews.comChardan Capital Reaffirms "Buy" Rating for Avidity Biosciences (NASDAQ:RNA)May 14, 2024 | americanbankingnews.comNeedham & Company LLC Reiterates "Buy" Rating for Avidity Biosciences (NASDAQ:RNA)May 13, 2024 | markets.businessinsider.comAvidity Biosciences: Strong Buy on Promising Trials and Solid FinancialsMay 10, 2024 | finanznachrichten.deAvidity Biosciences, Inc.: Avidity Biosciences Reports First Quarter 2024 Financial Results and Recent HighlightsMay 10, 2024 | investorplace.comRNA Stock Earnings: Avidity Biosciences Misses EPS, Beats Revenue for Q1 2024May 9, 2024 | seekingalpha.comAvidity Biosciences files automatic mixed shelfMay 9, 2024 | markets.businessinsider.comBuy Rating Justified for Avidity Biosciences Amid Strong Drug Candidate Prospects and Regulatory AdvancementsMay 9, 2024 | prnewswire.comAvidity Biosciences Reports First Quarter 2024 Financial Results and Recent HighlightsMay 8, 2024 | markets.businessinsider.comAvidity Receives Breakthrough Therapy Designation For Its Myotonic Dystrophy Type 1 Drug CandidateMay 8, 2024 | msn.comAvidity gets FDA breakthrough therapy status for DM1 drugMay 8, 2024 | prnewswire.comAvidity Biosciences to Participate in Upcoming Investor ConferenceMay 8, 2024 | finance.yahoo.comAvidity Biosciences Receives FDA Breakthrough Therapy Designation for Delpacibart Etedesiran (AOC 1001) for Treatment of Myotonic Dystrophy Type 1May 4, 2024 | msn.comB of A Securities Initiates Coverage of Avidity Biosciences (RNA) with Buy RecommendationSee More Headlines Receive RNA Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Avidity Biosciences and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings5/15/2024Today5/23/2024Next Earnings (Estimated)8/13/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Pharmaceutical preparations Sub-IndustryN/A Current SymbolNASDAQ:RNA CUSIPN/A CIK1574111 Webwww.aviditybiosciences.com Phone858-401-7900FaxN/AEmployees253Year FoundedN/APrice Target and Rating Average Stock Price Target$41.33 High Stock Price Target$60.00 Low Stock Price Target$30.00 Potential Upside/Downside+39.5%Consensus RatingBuy Rating Score (0-4)3.00 Research Coverage6 Analysts Profitability EPS (Most Recent Fiscal Year)($2.95) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-212,220,000.00 Net Margins-2,103.78% Pretax Margin-2,103.78% Return on Equity-37.98% Return on Assets-33.09% Debt Debt-to-Equity RatioN/A Current Ratio12.47 Quick Ratio12.47 Sales & Book Value Annual Sales$9.56 million Price / Sales296.32 Cash FlowN/A Price / Cash FlowN/A Book Value$8.69 per share Price / Book3.41Miscellaneous Outstanding Shares95,640,000Free Float92,118,000Market Cap$2.83 billion OptionableOptionable Beta0.79 These 7 Stocks Will Be Magnificent in 2024With average gains of 150% since the start of 2023, now is the time to give these stocks a look and pump up your 2024 portfolio.Get This Free Report Key ExecutivesDr. Troy Edward Wilson J.D. (Age 55)Ph.D., Co-Founder & Independent Chairman Comp: $70kMs. Sarah Boyce (Age 52)President, CEO & Director Comp: $998.88kMr. Michael F. MacLean (Age 58)Chief Financial & Chief Business Officer Comp: $674.74kDr. W. Michael F. Flanagan Ph.D. (Age 61)Chief Scientific & Technical Officer Comp: $675.22kMs. Teresa McCarthy (Age 60)Chief Human Resources Officer Comp: $628.79kDr. Arthur A. Levin Ph.D. (Age 70)Distinguished Scientist, Strategic Leader & Director Comp: $304.69kMr. Eric B. Mosbrooker (Age 57)Chief Strategy Officer Comp: $45kProf. Mark E. Davis Ph.D.Scientific Founder, Member of Scientific Advisory Board and Member of Board of ManagersDr. Frank P. McCormick Ph.D. (Age 74)Scientific Founder & Member of Scientific Advisory Board Mr. Geoffrey M. Grande C.F.A.VP of Investor Relation & Corporate CommunicationMore ExecutivesKey CompetitorsDyne TherapeuticsNASDAQ:DYNMorphoSysNASDAQ:MORMaravai LifeSciencesNASDAQ:MRVIAmicus TherapeuticsNASDAQ:FOLDXenon PharmaceuticalsNASDAQ:XENEView All CompetitorsInsiders & InstitutionsArthur A LevinSold 5,000 sharesTotal: $149,500.00 ($29.90/share)RA Capital Management L.P.Bought 827,647 shares on 5/17/2024Ownership: 3.432%Alethea Capital Management LLCSold 93,954 shares on 5/17/2024Ownership: 0.795%Janus Henderson Group PLCBought 1,216,730 shares on 5/16/2024Ownership: 1.299%California State Teachers Retirement SystemBought 6,618 shares on 5/16/2024Ownership: 0.075%View All Insider TransactionsView All Institutional Transactions RNA Stock Analysis - Frequently Asked Questions Should I buy or sell Avidity Biosciences stock right now? 6 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Avidity Biosciences in the last year. There are currently 6 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "buy" RNA shares. View RNA analyst ratings or view top-rated stocks. What is Avidity Biosciences' stock price target for 2024? 6 Wall Street research analysts have issued 1-year price objectives for Avidity Biosciences' stock. Their RNA share price targets range from $30.00 to $60.00. On average, they anticipate the company's stock price to reach $41.33 in the next twelve months. This suggests a possible upside of 46.1% from the stock's current price. View analysts price targets for RNA or view top-rated stocks among Wall Street analysts. How have RNA shares performed in 2024? Avidity Biosciences' stock was trading at $9.05 at the beginning of the year. Since then, RNA stock has increased by 212.7% and is now trading at $28.30. View the best growth stocks for 2024 here. When is Avidity Biosciences' next earnings date? The company is scheduled to release its next quarterly earnings announcement on Tuesday, August 13th 2024. View our RNA earnings forecast. How were Avidity Biosciences' earnings last quarter? Avidity Biosciences, Inc. (NASDAQ:RNA) announced its quarterly earnings results on Wednesday, May, 15th. The biotechnology company reported ($0.79) earnings per share (EPS) for the quarter, beating analysts' consensus estimates of ($0.81) by $0.02. The biotechnology company had revenue of $3.54 million for the quarter, compared to analysts' expectations of $7.09 million. Avidity Biosciences had a negative trailing twelve-month return on equity of 37.98% and a negative net margin of 2,103.78%. What ETFs hold Avidity Biosciences' stock? ETFs with the largest weight of Avidity Biosciences (NASDAQ:RNA) stock in their portfolio include Direxion Moonshot Innovators ETF (MOON), Simplify Propel Opportunities ETF (SURI), Global X Genomics & Biotechnology ETF (GNOM), Morningstar US Small Growth (MSGR), Virtus LifeSci Biotech Clinical Trials ETF (BBC), Invesco Dorsey Wright Healthcare Momentum ETF (PTH), ALPS Medical Breakthroughs ETF (SBIO) and Harbor Disruptive Innovation ETF (INNO). What other stocks do shareholders of Avidity Biosciences own? Based on aggregate information from My MarketBeat watchlists, some companies that other Avidity Biosciences investors own include GTX (GTXI), Inovio Pharmaceuticals (INO), Novavax (NVAX), Sarepta Therapeutics (SRPT), Avid Bioservices (CDMO), Dynavax Technologies (DVAX), iBio (IBIO), Intel (INTC), Ariad Pharmaceuticals (ARIA) and Corcept Therapeutics (CORT). When did Avidity Biosciences IPO? Avidity Biosciences (RNA) raised $150 million in an initial public offering (IPO) on Friday, June 12th 2020. The company issued 10,000,000 shares at $14.00-$16.00 per share. Cowen, SVB Leerink, Credit Suisse and Wells Fargo Securities acted as the underwriters for the IPO. Who are Avidity Biosciences' major shareholders? Avidity Biosciences' stock is owned by a number of retail and institutional investors. Top institutional shareholders include Price T Rowe Associates Inc. MD (7.77%), Avoro Capital Advisors LLC (6.09%), Vanguard Group Inc. (4.02%), RA Capital Management L.P. (3.43%), Janus Henderson Group PLC (1.30%) and Alethea Capital Management LLC (0.80%). Insiders that own company stock include Arthur A Levin, Michael F Maclean, Rtw Investments, Lp, Sarah Boyce and W Michael Flanagan. View institutional ownership trends. How do I buy shares of Avidity Biosciences? Shares of RNA stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. This page (NASDAQ:RNA) was last updated on 5/23/2024 by MarketBeat.com Staff From Our PartnersThis could mean the end of the U.S dollar…Colonial MetalsTech GIANT’s Plans to Revolutionize Crypto…Crypto 101 MediaElon to Transform U.S. Economy? Porter & CompanyHe Is Giving Away BitcoinCrypto Swap ProfitsBill Clinton Backing Biden Replacement???The Freeport SocietyThe Presidential candidate you should REALLY be worried aboutStansberry ResearchWrite this ticker symbol down…StocksToTrade$1,500 to $9,400 in one month? (A.I. Trade List)Prosper Trading Academy Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Avidity Biosciences, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
